OR WAIT null SECS
Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.
April 09, 2021
Even before Emergent disclosed that it had to discard 15 million doses of the J&J vaccine drug substance, FDA inspectors had uncovered multiple deficiencies and quality control issues.
April 02, 2021
Concerns over vulnerability in the supply chain has increased pressure on FDA to renew site visits of domestic and foreign facilities.
The White House’s American Jobs Plan includes investment in new technologies for rapid scale up of vaccine production, in expanded emergency production capacity and enhanced US infrastructure for biopreparedness, and in greater production onshore of APIs.
March 29, 2021
The need for added revenues to fund billion-dollar infrastructure improvements has fueled challenges to industry pricing practices.